Taylor Wessing has advised a series of eight biotech companies on their concurrent sale into Centessa Pharmaceuticals, a newly established holding company for a group of 10 life sciences companies in Europe and North America.
Taylor Wessing acts on transformational roll-up and $250 million crossover financing of cutting-edge UK and European biotech companies
Centessa Pharmaceuticals is involved in the development of innovative new treatments. Taylor Wessing advised ApcinteX, Capella Biosciences, Inexia, LockBody Therapeutics, Morphogen-IX, Orexia, Pega-One and Z Factor on their participation in the deal.
This complex deal was led by Ross McNaughton and Ed Chapman, with IP support led by life sciences specialist Colin McCall. The transaction involved advice from across the firm’s corporate, patent, tax and incentives groups. The deal underlines the firm's strong position in the Cambridge and wider UK market, working with companies and investors in the biotech space.
Taylor Wessing is a full-service international law firm, working with clients in the world’s most dynamic industries. We take a single-minded approach to advising our clients, helping them succeed by thinking innovatively about their business issues. We support clients wherever they want to do business. The firm has a sector focus with experts in technology, media and communications, life sciences and private